Ascendis Pharma A (ASND) Non-Current Deffered Revenue (2017 - 2026)
Ascendis Pharma A (ASND) posted Non-Current Deffered Revenue of $6.3 million for Q1 2026, up 9.12% sequentially from $5.8 million in Q4 2025, and up 401.69% YoY from $1.3 million in Q1 2025.
Ascendis Pharma A (ASND) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Ascendis Pharma A has reported Non-Current Deffered Revenue for 10 years, with the latest figure at $6.3 million in Q1 2026.
- Quarterly Non-Current Deffered Revenue rose 401.69% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (up 401.69% YoY) and the FY2025 annual result came in at $5.8 million, up 7.71% from the prior year.
- Non-Current Deffered Revenue climbed to $6.3 million in Q1 2026 per ASND's latest filing, from $5.8 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $13.3 million in Q3 2022 and troughed at -$10.1 million in Q3 2023.
- A 5-year average of $4.0 million and a median of $5.4 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue jumped 3539.29% in 2022, then sank 351.48% in 2023.
- Over 5 years, Non-Current Deffered Revenue stood at $8.8 million in 2022, then declined by 27.45% to $6.4 million in 2023, then decreased by 16.53% to $5.3 million in 2024, then grew by 7.71% to $5.8 million in 2025, then grew by 9.12% to $6.3 million in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $6.3 million, $5.8 million, and $4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 6.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.28 Mn |
| Dec 31, 2025 | 5.76 Mn |
| Sep 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | 5.34 Mn |
| Sep 30, 2024 | 5.49 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Mar 31, 2024 | 5.43 Mn |
| Dec 31, 2023 | 6.40 Mn |
| Sep 30, 2023 | -10.05 Mn |
| Jun 30, 2023 | -9.93 Mn |
| Mar 31, 2023 | 10.73 Mn |
| Dec 31, 2022 | 8.82 Mn |
| Sep 30, 2022 | 13.26 Mn |
| Jun 30, 2022 | 3.95 Mn |
| Mar 31, 2022 | 3.33 Mn |
| Dec 31, 2021 | 5.95 Mn |
| Sep 30, 2021 | -385,626.95 |
| Jun 30, 2021 | -262,531.17 |